Loading...
XPARGNRO
Market cap2mUSD
Dec 20, Last price  
0.08EUR
1D
-15.37%
1Q
8.26%
Jan 2017
-99.25%
IPO
-99.37%
Name

Geneuro SA

Chart & Performance

D1W1MN
XPAR:GNRO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
342.90%
Rev. gr., 5y
30.91%
Revenues
0k
21,1007,305,5000014,948000000
Net income
-15m
L+20.96%
-3,498,8001,776,4000000-9,460,800-8,962,300-6,817,700-12,199,800-14,757,000
CFO
-10m
L-22.38%
-3,430,3002,949,10011,840000-10,141,700-7,432,800-6,784,700-13,072,500-10,147,000

Profile

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
URL
https://www.geneuro.com/
IPO date
Apr 15, 2016
Employees
16
Domiciled in
CH
Incorporated in
CH

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
15,653
13,039
7,513
Unusual Expense (Income)
NOPBT
(15,653)
(13,039)
(7,513)
NOPBT Margin
Operating Taxes
(552)
(1,314)
(1,007)
Tax Rate
NOPAT
(15,101)
(11,725)
(6,506)
Net income
(14,757)
20.96%
(12,200)
78.94%
(6,818)
-23.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,042
5,621
BB yield
-19.64%
-7.44%
Debt
Debt current
747
602
257
Long-term debt
13,416
1,242
959
Deferred revenue
Other long-term liabilities
1,270
6,186
4,623
Net debt
10,464
(3,749)
(4,264)
Cash flow
Cash from operating activities
(10,147)
(13,072)
(6,785)
CAPEX
(12)
(57)
(44)
Cash from investing activities
51
(57)
(44)
Cash from financing activities
6,323
13,117
5,391
FCF
(13,917)
(10,708)
(7,861)
Balance
Cash
1,827
5,593
5,480
Long term investments
1,872
Excess cash
3,700
5,593
5,480
Stockholders' equity
(13,812)
(25,693)
(15,399)
Invested Capital
17,693
34,406
25,008
ROIC
ROCE
EV
Common stock shares outstanding
24,843
23,898
21,280
Price
1.09
-27.33%
1.50
-57.75%
3.55
26.79%
Market cap
27,079
-24.46%
35,847
-52.55%
75,544
35.11%
EV
37,543
32,098
71,281
EBITDA
(15,359)
(12,751)
(7,213)
EV/EBITDA
Interest
953
269
41
Interest/NOPBT